NCT01478360View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

PHASE2TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Asthma
Interventions
DRUG

AIN457 (secukinumab)

Secukinumab intravenous injection

DRUG

Placebo

Placebo intravenous injection

Trial Locations (9)

10117

Novartis Investigative Site, Berlin

22927

Novartis Investigative Site, Großhansdorf

55131

Novartis Investigative Site, Mainz

60596

Novartis Investigative Site, Frankfurt

65187

Novartis Investigative Site, Wiesbaden

SE11YR

Novartis Investigative Site, London

LE3 9QP

Novartis Investigative Site, Leicester

SW3 6PH

Novartis Investigative Site, London

M23 9QZ

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY